The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
Open accessAbstract
F-FDG for treatment monitoring in patients with lymphoma is one of the most well-developed clinical applications. PET/CT is nowadays used during treatment to assess chemosensitivity, with response-adapted therapy given according to 'interim' PET in clinical practice to adults and children with Hodgkin lymphoma. PET is also used to assess remission from disease and to predict prognosis in the pretransplant setting. Mature data have been reported for the common subtypes of aggressive B-cell lymphomas, with more recent data also supporting the use of PET for response assessment in T-cell lymphomas. The Deauville five-point scale incorporating the Deauville criteria (DC) is recommended for response assessment in international guidelines. FDG uptake is graded in relation to the reference regions of normal mediastinum and liver. The DC have been validated in most lymphoma subtypes. The DC permit the threshold for adequate or inadequate response to be adapted according to the clinical context or research question. It is important for PET readers to understand how the DC have been applied in response-adapted trials for correct interpretation and discussion with the multidisciplinary team. Quantitative methods to perform PET in standardized ways have also been developed which may further improve response assessment including a quantitative extension to the DC (qPET). This may have advantages in providing a continuous scale to refine the threshold for adequate/inadequate response in specific clinical situations or treatment optimization in trials. qPET is also less observer-dependent and limits the problem of optical misinterpretation due to the influence of background activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Self-citationRevised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Boellaard, R., Delgado-Bolton, R., Oyen, W. J. G., Giammarile, F., Tatsch, K., Eschner, W., Verzijlbergen, F. J., Barrington, S. F., Pike, L. C., Weber, W. A., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2961-x · Cited by 3,303 · cited 1×
“In response evaluation, this effect may compromise both the visual Deauville scoring and the quantitative tumour-to-reference organ SUV ratios [74, 75], For response classification, it is therefore important to use standardized reconstruction methods as defined in the EANM procedure guideline for tumour imaging, espec…”
MethodSelf-citationAppio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Self-citationYounes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2305 · Cited by 1,335
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
Boellaard, R., O’Doherty, M. J., Weber, W. A., Mottaghy, F. M., Lonsdale, M. N., Stroobants, S. G., Oyen, W. J. G., Kotzerke, J., Hoekstra, O. S., Pruim, J., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1297-4 · Cited by 1,326
Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6525 · Cited by 846
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., d’Amore, F., Enblad, G., Franceschetto, A., Fulham, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510093 · Cited by 818
Self-citationResults of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., Wimperis, J., Culligan, D., Popova, B., Smith, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408648 · Cited by 762
Self-citationReport on the First International Workshop on interim-PET scan in lymphoma
Meignan, M., Gallamini, A., Meignan, M., Gallamini, A., & Haioun, C. (2009) · Leukemia & Lymphoma · doi:10.1080/10428190903040048 · Cited by 754
Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.-M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2252 · Cited by 726
Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., Král, Z., Fuchs, M., Hallek, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61940-5 · Cited by 635
Self-citationSpecht, L., Yahalom, J., Illidge, T., Berthelsen, A. K., Constine, L. S., Eich, H. T., Girinsky, T., Hoppe, R. T., Mauch, P., Mikhaeel, N. G., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.05.005 · Cited by 582
Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., Vanuytsel, L., Bormans, G., Balzarini, J., De Wolf-Peeters, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.414 · Cited by 465
Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf256 · Cited by 410
Mikhaeel, N. G., Hutchings, M., Fields, P. A., O'Doherty, M. J., & Timothy, A. R. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi272 · Cited by 401
Boellaard, R., Oyen, W. J. G., Hoekstra, C. J., Hoekstra, O. S., Visser, E. P., Willemsen, A. T., Arends, B., Verzijlbergen, F. J., Zijlstra, J., Paans, A. M., et al. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0874-2 · Cited by 396
Lin, C., Itti, E., Haioun, C., Petegnief, Y., Luciani, A., Dupuis, J., Paone, G., Talbot, J.-N., Rahmouni, A., & Meignan, M. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.042093 · Cited by 394
Juweid, M. E., Wiseman, G. A., Vose, J. M., Ritchie, J. M., Menda, Y., Wooldridge, J. E., Mottaghy, F. M., Rohren, E. M., Blumstein, N. M., Stolpen, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.891 · Cited by 387
Raemaekers, J. M. M., André, M. P. E., Federico, M., Girinsky, T., Oumedaly, R., Brusamolino, E., Brice, P., Fermé, C., van der Maazen, R., Gotti, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.9298 · Cited by 387
18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
Weiler-Sagie, M., Bushelev, O., Epelbaum, R., Dann, E. J., Haim, N., Avivi, I., Ben-Barak, A., Ben-Arie, Y., Bar-Shalom, R., & Israel, O. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.067892 · Cited by 382
Barrington, S. F., Qian, W., Somer, E. J., Franceschetto, A., Bagni, B., Brun, E., Almquist, H., Loft, A., Højgaard, L., Federico, M., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1490-5 · Cited by 348
Self-citationUse of PET for monitoring cancer therapy and for predicting outcome.
Weber, W. (2005) · PubMed · Cited by 341
Römer, W., Hanauske, A.-R., Ziegler, S. I., Thödtmann, R., Weber, W., Fuchs, C., Enne, W., Herz, M., Nerl, C., Garbrecht, M., et al. (1998) · PubMed · doi:10.1182/blood.v91.12.4464 · Cited by 335
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
Hutchings, M., Mikhaeel, N. G., Fields, P. A., Nunan, T., & Timothy, A. R. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi200 · Cited by 327
Illidge, T., Specht, L., Yahalom, J., Aleman, B., Berthelsen, A. K., Constine, L., Dabaja, B., Dharmarajan, K., Ng, A., Ricardi, U., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.01.006 · Cited by 314
Biggi, A., Gallamini, A., Chauvie, S., Hutchings, M., Kostakoglu, L., Gregianin, M., Meignan, M., Malkowski, B., Hofman, M. S., & Barrington, S. F. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.110890 · Cited by 311
Self-citationImaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
Newman, J. S., Francis, I. R., Kaminski, M. S., & Wahl, R. L. (1994) · Radiology · doi:10.1148/radiology.190.1.8259386 · Cited by 265
Itti, E., Meignan, M., Berriolo-Riedinger, A., Biggi, A., Cashen, A. F., Véra, P., Tilly, H., Siegel, B. A., Gallamini, A., Casasnovas, R.-O., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2435-6 · Cited by 255
Mikhaeel, N. G., Timothy, A. R., O’Doherty, M. J., Hain, S. F., & Maisey, M. N. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009113384 · Cited by 248
小林, 洋. (2007) · Mebio oncology · Cited by 242
Pregno, P., Chiappella, A., Bellò, M., Botto, B., Ferrero, S., Franceschetti, S., Giunta, F., Ladetto, M., Limerutti, G., Menga, M., et al. (2012) · Blood · doi:10.1182/blood-2011-06-359943 · Cited by 236
PET/CT for Therapy Response Assessment in Lymphoma
Hutchings, M., & Barrington, S. F. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057190 · Cited by 220
Self-citationDupuis, J., Berriolo-Riedinger, A., Julian, A., Brice, P., Tychyj-Pinel, C., Tilly, H., Mounier, N., Gallamini, A., Feugier, P., Soubeyran, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0934 · Cited by 191
Mamot, C., Klingbiel, D., Hitz, F., Renner, C., Pabst, T., Driessen, C., Mey, U., Pless, M., Bargetzi, M., Krasniqi, F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9846 · Cited by 186
Trotman, J., Luminari, S., Boussetta, S., Versari, A., Dupuis, J., Tychyj, C., Marcheselli, L., Berriolo-Riedinger, A., Franceschetto, A., Julian, A., et al. (2014) · The Lancet Haematology · doi:10.1016/s2352-3026(14)70008-0 · Cited by 182
Spaepen, K., Stroobants, S., Dupont, P., Thomas, J., Vandenberghe, P., Balzarini, J., De Wolf‐Peeters, C., Mortelmans, L., & Verhoef, G. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03169.x · Cited by 169
Safar, V., Dupuis, J., Itti, E., Jardin, F., Fruchart, C., Bardet, S., Véra, P., Copie-Bergman, C., Rahmouni, A., Tilly, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2648 · Cited by 162
Cerci, J. J., Pracchia, L. F., Linardi, C. C. G., Pitella, F. A., Delbeke, D., Izaki, M., Trindade, E. M., Soares, J., Buccheri, V., & Meneghetti, J. C. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073197 · Cited by 157
Hasenclever, D., Kurch, L., Mauz-Körholz, C., Elsner, A., Georgi, T., Wallace, H., Landman-Parker, J., Moryl-Bujakowska, A., Cepelová, M., Karlén, J., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2715-9 · Cited by 157
Self-citationRecovery correction for quantitation in emission tomography: a feasibility study
Geworski, L., Knoop, B. O., de Cabrejas, M. L., Knapp, W. H., & Munz, D. L. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050022 · Cited by 156
Micallef, I. N., Maurer, M. J., Wiseman, G. A., Nikcevich, D. A., Kurtin, P. J., Cannon, M. W., Pérez, D. G., Soori, G. S., Link, B. K., Habermann, T. M., et al. (2011) · Blood · doi:10.1182/blood-2011-02-336990 · Cited by 147
Sunderland, J. J., & Christian, P. E. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.148056 · Cited by 145
Minn, H. R. I., Clavo, A. C., Grenman, R. A., & Wahl, R. L. (1995) · PubMed · Cited by 143
Scheuermann, J. S., Saffer, J. R., Karp, J. S., Levering, A., & Siegel, B. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057455 · Cited by 126
Tomasi, G., Turkheimer, F., & Aboagye, E. O. (2011) · Molecular Imaging and Biology · doi:10.1007/s11307-011-0514-2 · Cited by 116
Akamatsu, G., Mitsumoto, K., Taniguchi, T., Tsutsui, Y., Baba, S., & Sasaki, M. (2014) · European Journal of Radiology · doi:10.1016/j.ejrad.2013.09.030 · Cited by 96
Itti, E., Juweid, M. E., Haïoun, C., Yeddes, I., Hamza-Maaloul, F., Bez, I. E., Evangelista, E., Lin, C., Dupuis, J., & Meignan, M. A. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.080556 · Cited by 94
Roux, P. L., Gastinne, T., Gouill, S. L., Nowak, E., Bodet‐Milin, C., Querellou, S., Mahé, B., Dubruille, V., Blin, N., Salaün, P., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1741-0 · Cited by 90
Yang, D., Min, J., Song, H., Jeong, Y. Y., Chung, W., Bae, S.-Y., Ahn, J., Kim, Y., Bom, H., Chung, I., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.12.027 · Cited by 88
Carr, R. A., Fanti, S., Páez, D., Cerci, J. J., Györke, T., Redondo, F., Morris, T. P., Meneghetti, C., Auewarakul, C. U., Nair, R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.145326 · Cited by 78
Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP
Yoo, C., Lee, D. H., Kim, J. E., Jo, J., Yoon, D. H., Sohn, B. S., Kim, S., Lee, J., & Suh, C. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1135-6 · Cited by 77
Nols, N., Mounier, N., Bouazza, S., Lhommel, R., Costantini, S., Borght, T. V., Vekemans, M., Sonet, A., Bosly, A., Michaux, L., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.831848 · Cited by 73
18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma
Casulo, C., Schöder, H. M., Feeney, J. N., Lim, R., Maragulia, J. C., Zelenetz, A. D., & Horwitz, S. M. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.767901 · Cited by 72
Kuhnert, G., Boellaard, R., Sterzer, S., Kahraman, D., Scheffler, M., Wolf, J., Dietlein, M., Drzezga, A. E., & Kobe, C. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3165-8 · Cited by 70
Barrington, S. F., Mackewn, J. E., Schleyer, P., Marsden, P. K., Mikhaeel, N. G., Qian, W., Mouncey, P., Patrick, P., Popova, B., Johnson, P., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq428 · Cited by 66
Self-citationMidtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma
Zinzani, P. L., Gandolfi, L., Broccoli, A., Argnani, L., Fanti, S., Pellegrini, C., Stefoni, V., Derenzini, E., Quirini, F., & Baccarani, M. (2010) · Cancer · doi:10.1002/cncr.25579 · Cited by 64
When should FDG ‐ PET be used in the modern management of lymphoma?
Barrington, S. F., & Mikhaeel, N. G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12601 · Cited by 63
Self-citationKluge, R., Chavdarova, L., Hoffmann, M., Kobe, C., Malkowski, B., Montravers, F., Kurch, L., Georgi, T., Dietlein, M., Wallace, W. H., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149072 · Cited by 56
Self-citationInterim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma
Fuertes, S., Setoaín, X., López‐Guillermo, A., Carrasco, J. L., Rodríguez, S., Rovira, J., & Pons, F. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2320-8 · Cited by 56
Annunziata, S., Cuccaro, A., Calcagni, M. L., Hohaus, S., Giordano, A., & Rufini, V. (2016) · Annals of Nuclear Medicine · doi:10.1007/s12149-016-1092-9 · Cited by 47
Ceriani, L., Martelli, M., Gospodarowicz, M. K., Ricardi, U., Ferreri, A. J. M., Chiappella, A., Stelitano, C. C., Balzarotti, M., Cabrera, M. E., Cunningham, D., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.09.031 · Cited by 43
Yang, F., Zhang, Y., Yang, Z., Ying, Z., Zhou, N., Liu, C., Song, Y., Zhu, J., & Wang, X. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1277384 · Cited by 41
Kurch, L., Mauz‐Körholz, C., Bertling, S., Wallinder, M., Kaminska, M., Marwede, D., Tchavdarova, L., Georgi, T., Elsner, A., Barthel, A., et al. (2013) · Klinische Pädiatrie · doi:10.1055/s-0033-1354416 · Cited by 30
Self-citationStaging of Burkitt's lymphoma and response to treatment monitored by pet scanning
Barrington, S. F., & Carr, R. (1995) · Clinical Oncology · doi:10.1016/s0936-6555(05)80549-7 · Cited by 29
Self-citationDie Bedeutung des FDG-PET für die Stadieneinteilung und Therapie des Hodgkin-Lymphoms im Kindesalter
Kluge, R., & Körholz, D. (2011) · Klinische Pädiatrie · doi:10.1055/s-0031-1287834 · Cited by 28
Self-citationAlcantara, M., Dupuis, J., Mareschal, S., Julian, A., Cottereau, A., Becker, S., Dubois, S., Obéric, L., Huynh, A., Meignan, M. A., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2896-2 · Cited by 27
Ceriani, L., Barrington, S., Biggi, A., Malkowski, B., Metser, U., Versari, A., Martelli, M., Davies, A., Johnson, P. W., Zucca, E., et al. (2017) · Hematological Oncology · doi:10.1002/hon.2339 · Cited by 26
Self-citationQuak, E., Hovhannisyan, N., Lasnon, C., Fruchart, C., Vilque, J., Musafiri, D., & Aide, N. (2014) · Haematologica · doi:10.3324/haematol.2014.104125 · Cited by 25
Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?
Johnson, P. (2016) · Hematology · doi:10.1182/asheducation-2016.1.316 · Cited by 23
Zijlstra, J. M., Burggraaff, C. N., Kersten, M. J., & Barrington, S. F. (2016) · Haematologica · doi:10.3324/haematol.2016.142752 · Cited by 16
Self-citation
Cited by
Aide, N., Lasnon, C., Veit-Haibach, P., Sera, T., Sattler, B., & Boellaard, R. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3740-2 · Cited by 344
Trägårdh, E., Minarik, D., Almquist, H., Bitzén, U., Garpered, S., Hvittfelt, E., Olsson, B., & Oddstig, J. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0535-4 · Cited by 50
Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
Kuo, P. H., Benson, T., Messmann, R., & Groaning, M. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263638 · Cited by 56
Ly, J., Minarik, D., Edenbrandt, L., Wollmer, P., & Trägårdh, E. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0536-3 · Cited by 31
Metadata
- Authors
- Barrington, S. F., & Kluge, R.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2017-04-14
- Volume
- 44
- Issue
- S1
- Pages
- 97-110
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2606364858
- Cited by
- 281
- References
- 74
- FWCI
- 21.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.